fep blue glp-1 coverage 2025 for obesity treatment in 13 US states' Medicaid programs BCBS Dropping Anti-Obesity GLP-1s from

Endometriosis: early but promising signs Endometriosis affects roughly one in ten women of reproductive age

This includes: Structured dietary changes : Working with a dietitian to develop a sustainable, nutritionally balanced eating plan with an appropriate caloric deficit Regular physical activity : Gradually increasing to 150-300 minutes of moderate-intensity exercise weekly, as per UK Chief Medical Officers' guidelines Behavioural support : Accessing psychological interventions or NHS Talking Therapies to address eating behaviours and maintain motivation Regular monitoring : Attending follow-up appointments to assess weight loss progress, tolerability, and any emerging health concerns Patients should discuss any desire to use additional weight loss products with their healthcare team, who can provide evidence-based guidance tailored to individual circumstances

U.et al (2010)

Mantzoros CS, Flier JS

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (surmount-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Weekly injection makes it convenient